Nuclear Medicine Radioisotopes Market Size, Share and Growth Outlook 2026: By Type of Radioisotope, By Application, By Radiopharmaceutical Form, By End-User, Companies to 2034
The global Nuclear Medicine Radioisotopes Market size is forecast to increase from $8.34 Billion in 2026 to $18.14 Billion in 2034 at a CAGR of 10.2% between 2026 and 2034.
The Nuclear Medicine Radioisotopes market report provides detailed analysis and outlook of Nuclear Medicine Radioisotopes segments including By Type of Radioisotope (Diagnostic Radioisotopes, SPECT Radioisotopes, PET Radioisotopes, Therapeutic Radioisotopes, Alpha Emitters, Beta Emitters, Brachytherapy Isotopes ), By Application (Oncology, Cardiology, Neurology, Thyroid and Endocrine Disorders, Other Applications), By Radiopharmaceutical Form (Injectable, Oral Capsules / Solutions), By End-User (Hospitals, Diagnostic and Imaging Centers, Academic and Research Institutes) across global and regional markets. Further, analysis and outlook across 21 countries in North America, Europe, Asia Pacific, Middle East, Africa, and South America are provided in the study.
Nuclear Medicine Radioisotopes Industry Overview
Radioligand Therapy Expansion Driving Demand for Therapeutic Isotopes
The nuclear medicine radioisotopes industry is experiencing substantial transformation as radioligand therapies gain prominence in oncology and precision medicine. Healthcare providers are increasingly utilizing targeted radioactive isotopes to deliver therapeutic radiation directly to diseased tissues while minimizing exposure to surrounding healthy structures. This shift is creating significant demand for high-purity therapeutic isotopes such as Lutetium-177 and Actinium-225, which have become central components of next-generation cancer treatment strategies. Advances in radiopharmaceutical development, regulatory approvals, and clinical validation are accelerating adoption across oncology centers and nuclear medicine facilities worldwide. The industry's focus is increasingly directed toward establishing reliable isotope production networks capable of supporting growing therapeutic utilization.
Production Capacity Investments Strengthening Global Supply Infrastructure
Supply security has emerged as a strategic priority as demand for medical isotopes expands faster than historical production capabilities. Governments, producers, and healthcare stakeholders are investing heavily in new manufacturing infrastructure to ensure stable access to both therapeutic and diagnostic radioisotopes. SHINE Technologies achieved a major milestone with European authorization for Ilumira™, a non-carrier-added Lutetium-177 isotope intended for targeted radioligand therapies. Complementing this regulatory achievement, the company secured a substantial conditional loan commitment from the U.S. Department of Energy to support completion of its Chrysalis production facility, which is expected to become one of the largest medical isotope manufacturing sites globally. These investments reflect broader industry efforts to build resilient production ecosystems capable of supporting future radiopharmaceutical demand while reducing supply vulnerabilities.
Clinical Evidence and International Collaboration Supporting Industry Growth
Clinical validation and international coordination continue to shape the competitive landscape of the nuclear medicine radioisotopes sector. ITM Isotope Technologies Munich presented Phase 3 COMPETE trial data evaluating 177Lu-edotreotide in patients with neuroendocrine tumors, demonstrating statistically significant progression-free survival improvements compared with standard molecular therapy. Such findings reinforce the expanding clinical role of Lutetium-177-based therapies within precision oncology. At the same time, international stakeholders are collaborating to strengthen long-term isotope availability. The OECD Nuclear Energy Agency and the U.S. Department of Energy convened global policymakers and industry representatives to address supply chain resilience for critical isotopes including Actinium-225, Lutetium-177, and Molybdenum-99. These coordinated initiatives underscore the growing importance of secure isotope production, diversified supply chains, and international partnerships in supporting the continued advancement of nuclear medicine and radiopharmaceutical innovation.
Nuclear Medicine Radioisotopes Market Trends, Growth Drivers, Competitive Landscape, and Future Opportunities
The global Nuclear Medicine Radioisotopes market is witnessing increasing investments in innovation, product development, digital transformation, artificial intelligence integration, healthcare infrastructure expansion, and strategic partnerships across developed and emerging economies. Key Companies in the industry include- Curium , Cardinal Health, Inc. , Eckert & Ziegler Radiopharma , GE HealthCare Technologies Inc. , Telix Pharmaceuticals Ltd. , Lantheus Holdings, Inc. , BWX Technologies, Inc. (Nordion) , Jubilant Pharmova Limited , NTP Radioisotopes SOC Ltd. , Isotope Technologies Garching GmbH (ITM). The Nuclear Medicine Radioisotopes market is expected to remain one of the most closely watched segments in the global healthcare industry, with companies focusing on niche market segments. As healthcare systems across the US, Europe, Asia-Pacific, Latin America, and Middle East & Africa continue to prioritize efficiency, access, and innovation, the Nuclear Medicine Radioisotopes industry outlook remains shaped by rising healthcare expenditure, demographic change, digital transformation, and product innovation.
The report provides detailed market analysis including-
Leading companies in Nuclear Medicine Radioisotopes industry include- Curium , Cardinal Health, Inc. , Eckert & Ziegler Radiopharma , GE HealthCare Technologies Inc. , Telix Pharmaceuticals Ltd. , Lantheus Holdings, Inc. , BWX Technologies, Inc. (Nordion) , Jubilant Pharmova Limited , NTP Radioisotopes SOC Ltd. , Isotope Technologies Garching GmbH (ITM). The Nuclear Medicine Radioisotopes market remains moderately to highly fragmented, with competition expected to intensify as companies accelerate investments in innovation, geographic expansion, strategic partnerships, and portfolio diversification through 2034. In developed markets such as the United States, Germany, France, the United Kingdom, and Canada, competition is increasingly centered on innovation, reimbursement positioning, and value-based healthcare solutions. Meanwhile, emerging markets including China, India, Brazil, and countries across the Middle East and Africa continue to present significant opportunities for expansion due to rising healthcare expenditure, growing patient populations, and increasing access to healthcare services.
What to expect in US Nuclear Medicine Radioisotopes Markets in 2026 and beyond- Market Size, Share, Growth Rate, and Forecast to 2034
The US healthcare expenditure is forecast to reach $8.2 Trillion in 2034 from $5.5 Trillion in 2026 based on the National Health Expenditure Accounts (NHEA) data. With an aging population, rising chronic disease burden, and increasing migration toward minimally invasive and outpatient care, the Nuclear Medicine Radioisotopes market remains one of the strongest-performing segments in the country.
The US Nuclear Medicine Radioisotopes Companies are opting new business models, optimized pricing models, industry partnerships, and AI-enabled back end transformations to enhance efficiency and cost management. The US Nuclear Medicine Radioisotopes market faces successive waves of challenging trends, with strong opportunities across select segments. The CMS plan to implement Medicaid from 2027 is driving states to build eligibility verification systems throughout 2026. Looking ahead to 2034, we anticipate stronger results underpinned by opportunities exist across Nuclear Medicine Radioisotopes industry. On the medical device front, over 7,000 device manufacturers continue to gain from increasing demand from demand for implantable devices, surgical instruments, monitoring equipment, and diagnostic systems.
Canada- Proximity to the US and healthcare similarities to EU5 countries fuel sales of Canadian Nuclear Medicine Radioisotopes markets
Canada's strong Nuclear Medicine Radioisotopes sales performance is underpinned by an aging population and a well-developed healthcare infrastructure. Steady growth in new brand spending in rural and urban locations fuel the long-term prospects of small and medium-sized enterprises across medical, diagnostic, and therapeutic devices. The Canadian Nuclear Medicine Radioisotopes market presents significant opportunities for U.S. exporters of medical devices, with the U.S. being Canada’s largest trading partner for this sector. Potential advantages including specialized materials, advanced manufacturing techniques, and digital technologies support the launch of new products in the country.
Germany Nuclear Medicine Radioisotopes Trends and Perspectives to 2034- Financial sustainability, hospital restructuring, demographic pressures, and digitization of care delivery continue to shape the German healthcare industry.
Germany continues to remain the largest Nuclear Medicine Radioisotopes market in Europe, driven by over €600 Billion healthcare expenditure, €12 Billion medical device R&D expenditure, statutory health insurance system covering 90% German population, nationwide rollout of the electronic patient record (ePA), and large-volume of Nuclear Medicine Radioisotopes population. In particular, Research and development in Germany fuels the commercialization of cutting-edge technologies. Companies across the Germany Nuclear Medicine Radioisotopes industry value chain are focusing on both domestic markets and exports. The country is also driving digital adoption with the Hospital Future Act driving hospitals to upgrade their information systems by 2027. Over the forecast period, aging population, rising healthcare costs, and increasing procedural volumes drive the Nuclear Medicine Radioisotopes market outlook.
France Market Size, Growth Rate, and Forecast Analysis to 2034- Universal healthcare system, high public healthcare expenditure, and strong government support Nuclear Medicine Radioisotopes sales through 2034
France Nuclear Medicine Radioisotopes companies are emphasizing on opportunities for rapid, at-scale innovation to boost profitability over the long-term. The country’s National Health Insurance spending target (ONDAM) estimates 3.7% growth in the country’s healthcare expenditure. Over the forecast period, expenditure control measures, chronic disease management initiatives, workforce reforms, and efforts to improve system efficiency drive the long-term prospects.
The biggest 2026 policy frame is the PLFSS 2026. The law sets the Maladie branch spending target at €271.4 billion for 2026 and fixes the ONDAM at €117.5 billion for city care, €112.8 billion for health establishments, and €18.3 billion for elderly-care establishments and services. France’s market is also being pulled by demographics. INSEE estimates that on 1 January 2026 France had 69.1 million inhabitants, with 22% aged 65 or over. INSEE also reported that 2025 births were 645,000 and deaths were 651,000, producing a negative natural balance of about 6,000 for the first time since the end of the Second World War.
UK Nuclear Medicine Radioisotopes Market Size, Share, and Growth Projections to 2034- Rapid growth driven by new and existing brands across the industry value chain
Small high-need consumer segments remain key priority of Nuclear Medicine Radioisotopes distributors in the UK industry. Continuous launch of new products coupled with high expenditures support the market outlook. The UK Government financing remains the dominant funding source at 81.3% of total healthcare expenditure, or ?280 billion in 2025. According to the ONS, total healthcare spending grew 7.7% nominally and 3.9% in real terms from 2024 to 2025. Similarly, out-of-pocket spending was ?49 billion (14.1%) and voluntary health insurance was ?9.5 billion (2.8%). The market is driven by rapid digital adoption with NHS England’s plan to give more than 500,000 staff access to new AI tools.
China Nuclear Medicine Radioisotopes Market Growth Drivers, Revenue Trends, and Forecast- Medical insurance coverage is rapidly expanding over the past few years
China Nuclear Medicine Radioisotopes market is undergoing a structural shift from hospital-centric care toward a more integrated system emphasizing primary care, outpatient services, and long-term care. Chinese local players are emerging as a strong pillar of Nuclear Medicine Radioisotopes industry, offering opportunities for both competition and partnership. Over the forecast period, new and innovative product launches remain key elements driving market outlook. China's healthcare industry is increasingly centered on expanding healthcare capacity, improving access to advanced treatments, and reducing dependence on imported technologies.
The National Healthcare Security Administration reported that by end-2024, China’s basic medical insurance covered 1.32662 billion people and the coverage rate was 95%. Regional disparities in consumer spending trends continue to become more pronounced in the Chinese Nuclear Medicine Radioisotopes industry. Over the forecast period, demand will keep shifting toward geriatrics, chronic disease management, rehabilitation, long-term care, and outpatient care, while pricing pressure will remain intense in drugs and consumables because reimbursement.
India Nuclear Medicine Radioisotopes Market Landscape: Current Size and Long-Term Growth Outlook - Increased pricing pressures in US market is encouraging domestic vendors to expand across India
Indian Nuclear Medicine Radioisotopes market is witnessing the rapid emergence of an ecosystem that brings together diverse companies across the industry value chain. Further, large-scale healthcare public and private investments and a steady growth in chronic conditions is driving sales of pharmaceuticals and medical devices. Further, non-retail channel is experiencing volume decrease and patients are migrating to the retail. Indian medical device firms are also combining precision engineering with lower labor costs to make world-class diagnostics, robotics, and critical care devices.
Brazil Nuclear Medicine Radioisotopes market remains price-driven, with products domestically manufactured and accessibility offering potential opportunities
Healthcare expenditure in Brazil exceeds 10% of GDP, with the country among the highest healthcare spenders in Latin America. ANS reported 53.2 million medical-plan beneficiaries in December 2025, while IBGE projects a steady rise in older-age cohorts, with people aged 60+ already representing about 23% of the population. The price sensitive market access is broad through the public system, private coverage adds a sizeable premium layer, and reimbursement, procurement, and hospital efficiency remain key buying drivers.
Middle East and Africa Nuclear Medicine Radioisotopes Industry Trends and Perspectives to 2034
According to the World Bank, the Middle East and North Africa population exceeds 500 million, while Sub-Saharan Africa's population exceeds 1.2 billion, making the broader MEA region one of the fastest-growing healthcare demand centers globally. The GCC countries including Saudi Arabia, United Arab Emirates, Qatar, and Kuwait continue to account for a disproportionately large share of regional healthcare spending. Government-led programs such as Saudi Arabia's Vision 2030 are accelerating investments in hospital infrastructure, private-sector participation, medical technology adoption, and healthcare digitalization. On the other hand, South Africa, Egypt, Nigeria, and Kenya remain key healthcare markets due to their large populations, expanding private healthcare sectors, and growing investments in healthcare delivery systems.
Nuclear Medicine Radioisotopes Market Segmentation
By Type of Radioisotope
Diagnostic Radioisotopes
SPECT Radioisotopes
PET Radioisotopes
Therapeutic Radioisotopes
Alpha Emitters
Beta Emitters
Brachytherapy Isotopes
By Application
Oncology
Cardiology
Neurology
Thyroid and Endocrine Disorders
Other Applications
By Radiopharmaceutical Form
Injectable
Oral Capsules / Solutions
By End-User
Hospitals
Diagnostic and Imaging Centers
Academic and Research Institutes
Leading Companies in Nuclear Medicine Radioisotopes Industry (2026)
Curium
Cardinal Health, Inc.
Eckert & Ziegler Radiopharma
GE HealthCare Technologies Inc.
Telix Pharmaceuticals Ltd.
Lantheus Holdings, Inc.
BWX Technologies, Inc. (Nordion)
Jubilant Pharmova Limited
NTP Radioisotopes SOC Ltd.
Isotope Technologies Garching GmbH (ITM)
Countries Included
The Nuclear Medicine Radioisotopes market report provides detailed analysis and outlook of Nuclear Medicine Radioisotopes segments including By Type of Radioisotope (Diagnostic Radioisotopes, SPECT Radioisotopes, PET Radioisotopes, Therapeutic Radioisotopes, Alpha Emitters, Beta Emitters, Brachytherapy Isotopes ), By Application (Oncology, Cardiology, Neurology, Thyroid and Endocrine Disorders, Other Applications), By Radiopharmaceutical Form (Injectable, Oral Capsules / Solutions), By End-User (Hospitals, Diagnostic and Imaging Centers, Academic and Research Institutes) across global and regional markets. Further, analysis and outlook across 21 countries in North America, Europe, Asia Pacific, Middle East, Africa, and South America are provided in the study.
Nuclear Medicine Radioisotopes Industry Overview
Radioligand Therapy Expansion Driving Demand for Therapeutic Isotopes
The nuclear medicine radioisotopes industry is experiencing substantial transformation as radioligand therapies gain prominence in oncology and precision medicine. Healthcare providers are increasingly utilizing targeted radioactive isotopes to deliver therapeutic radiation directly to diseased tissues while minimizing exposure to surrounding healthy structures. This shift is creating significant demand for high-purity therapeutic isotopes such as Lutetium-177 and Actinium-225, which have become central components of next-generation cancer treatment strategies. Advances in radiopharmaceutical development, regulatory approvals, and clinical validation are accelerating adoption across oncology centers and nuclear medicine facilities worldwide. The industry's focus is increasingly directed toward establishing reliable isotope production networks capable of supporting growing therapeutic utilization.
Production Capacity Investments Strengthening Global Supply Infrastructure
Supply security has emerged as a strategic priority as demand for medical isotopes expands faster than historical production capabilities. Governments, producers, and healthcare stakeholders are investing heavily in new manufacturing infrastructure to ensure stable access to both therapeutic and diagnostic radioisotopes. SHINE Technologies achieved a major milestone with European authorization for Ilumira™, a non-carrier-added Lutetium-177 isotope intended for targeted radioligand therapies. Complementing this regulatory achievement, the company secured a substantial conditional loan commitment from the U.S. Department of Energy to support completion of its Chrysalis production facility, which is expected to become one of the largest medical isotope manufacturing sites globally. These investments reflect broader industry efforts to build resilient production ecosystems capable of supporting future radiopharmaceutical demand while reducing supply vulnerabilities.
Clinical Evidence and International Collaboration Supporting Industry Growth
Clinical validation and international coordination continue to shape the competitive landscape of the nuclear medicine radioisotopes sector. ITM Isotope Technologies Munich presented Phase 3 COMPETE trial data evaluating 177Lu-edotreotide in patients with neuroendocrine tumors, demonstrating statistically significant progression-free survival improvements compared with standard molecular therapy. Such findings reinforce the expanding clinical role of Lutetium-177-based therapies within precision oncology. At the same time, international stakeholders are collaborating to strengthen long-term isotope availability. The OECD Nuclear Energy Agency and the U.S. Department of Energy convened global policymakers and industry representatives to address supply chain resilience for critical isotopes including Actinium-225, Lutetium-177, and Molybdenum-99. These coordinated initiatives underscore the growing importance of secure isotope production, diversified supply chains, and international partnerships in supporting the continued advancement of nuclear medicine and radiopharmaceutical innovation.
Nuclear Medicine Radioisotopes Market Trends, Growth Drivers, Competitive Landscape, and Future Opportunities
The global Nuclear Medicine Radioisotopes market is witnessing increasing investments in innovation, product development, digital transformation, artificial intelligence integration, healthcare infrastructure expansion, and strategic partnerships across developed and emerging economies. Key Companies in the industry include- Curium , Cardinal Health, Inc. , Eckert & Ziegler Radiopharma , GE HealthCare Technologies Inc. , Telix Pharmaceuticals Ltd. , Lantheus Holdings, Inc. , BWX Technologies, Inc. (Nordion) , Jubilant Pharmova Limited , NTP Radioisotopes SOC Ltd. , Isotope Technologies Garching GmbH (ITM). The Nuclear Medicine Radioisotopes market is expected to remain one of the most closely watched segments in the global healthcare industry, with companies focusing on niche market segments. As healthcare systems across the US, Europe, Asia-Pacific, Latin America, and Middle East & Africa continue to prioritize efficiency, access, and innovation, the Nuclear Medicine Radioisotopes industry outlook remains shaped by rising healthcare expenditure, demographic change, digital transformation, and product innovation.
The report provides detailed market analysis including-
- Growth Nuclear Medicine Radioisotopes Market size outlook across 3 scenarios- High growth, reference, and Low growth cases
- Market Trends, Drivers, Potential Opportunities, and Challenges faced by Nuclear Medicine Radioisotopes companies
- Porter’s Five forces analysis- Bargaining power of buyers and sellers, Threat of Substitutes and new entrants, and Intensity of competitive rivalry
- Detailed SWOT Analysis of global and regional Nuclear Medicine Radioisotopes markets
- Competitive analysis including business description, product analysis, and financial profiles
- Key country specific analysis detailing key factors shaping the short-term and long-term outlook
- Recent industry developments and news including mergers, acquisitions, product launches, expansions, and company announcements
Leading companies in Nuclear Medicine Radioisotopes industry include- Curium , Cardinal Health, Inc. , Eckert & Ziegler Radiopharma , GE HealthCare Technologies Inc. , Telix Pharmaceuticals Ltd. , Lantheus Holdings, Inc. , BWX Technologies, Inc. (Nordion) , Jubilant Pharmova Limited , NTP Radioisotopes SOC Ltd. , Isotope Technologies Garching GmbH (ITM). The Nuclear Medicine Radioisotopes market remains moderately to highly fragmented, with competition expected to intensify as companies accelerate investments in innovation, geographic expansion, strategic partnerships, and portfolio diversification through 2034. In developed markets such as the United States, Germany, France, the United Kingdom, and Canada, competition is increasingly centered on innovation, reimbursement positioning, and value-based healthcare solutions. Meanwhile, emerging markets including China, India, Brazil, and countries across the Middle East and Africa continue to present significant opportunities for expansion due to rising healthcare expenditure, growing patient populations, and increasing access to healthcare services.
What to expect in US Nuclear Medicine Radioisotopes Markets in 2026 and beyond- Market Size, Share, Growth Rate, and Forecast to 2034
The US healthcare expenditure is forecast to reach $8.2 Trillion in 2034 from $5.5 Trillion in 2026 based on the National Health Expenditure Accounts (NHEA) data. With an aging population, rising chronic disease burden, and increasing migration toward minimally invasive and outpatient care, the Nuclear Medicine Radioisotopes market remains one of the strongest-performing segments in the country.
The US Nuclear Medicine Radioisotopes Companies are opting new business models, optimized pricing models, industry partnerships, and AI-enabled back end transformations to enhance efficiency and cost management. The US Nuclear Medicine Radioisotopes market faces successive waves of challenging trends, with strong opportunities across select segments. The CMS plan to implement Medicaid from 2027 is driving states to build eligibility verification systems throughout 2026. Looking ahead to 2034, we anticipate stronger results underpinned by opportunities exist across Nuclear Medicine Radioisotopes industry. On the medical device front, over 7,000 device manufacturers continue to gain from increasing demand from demand for implantable devices, surgical instruments, monitoring equipment, and diagnostic systems.
Canada- Proximity to the US and healthcare similarities to EU5 countries fuel sales of Canadian Nuclear Medicine Radioisotopes markets
Canada's strong Nuclear Medicine Radioisotopes sales performance is underpinned by an aging population and a well-developed healthcare infrastructure. Steady growth in new brand spending in rural and urban locations fuel the long-term prospects of small and medium-sized enterprises across medical, diagnostic, and therapeutic devices. The Canadian Nuclear Medicine Radioisotopes market presents significant opportunities for U.S. exporters of medical devices, with the U.S. being Canada’s largest trading partner for this sector. Potential advantages including specialized materials, advanced manufacturing techniques, and digital technologies support the launch of new products in the country.
Germany Nuclear Medicine Radioisotopes Trends and Perspectives to 2034- Financial sustainability, hospital restructuring, demographic pressures, and digitization of care delivery continue to shape the German healthcare industry.
Germany continues to remain the largest Nuclear Medicine Radioisotopes market in Europe, driven by over €600 Billion healthcare expenditure, €12 Billion medical device R&D expenditure, statutory health insurance system covering 90% German population, nationwide rollout of the electronic patient record (ePA), and large-volume of Nuclear Medicine Radioisotopes population. In particular, Research and development in Germany fuels the commercialization of cutting-edge technologies. Companies across the Germany Nuclear Medicine Radioisotopes industry value chain are focusing on both domestic markets and exports. The country is also driving digital adoption with the Hospital Future Act driving hospitals to upgrade their information systems by 2027. Over the forecast period, aging population, rising healthcare costs, and increasing procedural volumes drive the Nuclear Medicine Radioisotopes market outlook.
France Market Size, Growth Rate, and Forecast Analysis to 2034- Universal healthcare system, high public healthcare expenditure, and strong government support Nuclear Medicine Radioisotopes sales through 2034
France Nuclear Medicine Radioisotopes companies are emphasizing on opportunities for rapid, at-scale innovation to boost profitability over the long-term. The country’s National Health Insurance spending target (ONDAM) estimates 3.7% growth in the country’s healthcare expenditure. Over the forecast period, expenditure control measures, chronic disease management initiatives, workforce reforms, and efforts to improve system efficiency drive the long-term prospects.
The biggest 2026 policy frame is the PLFSS 2026. The law sets the Maladie branch spending target at €271.4 billion for 2026 and fixes the ONDAM at €117.5 billion for city care, €112.8 billion for health establishments, and €18.3 billion for elderly-care establishments and services. France’s market is also being pulled by demographics. INSEE estimates that on 1 January 2026 France had 69.1 million inhabitants, with 22% aged 65 or over. INSEE also reported that 2025 births were 645,000 and deaths were 651,000, producing a negative natural balance of about 6,000 for the first time since the end of the Second World War.
UK Nuclear Medicine Radioisotopes Market Size, Share, and Growth Projections to 2034- Rapid growth driven by new and existing brands across the industry value chain
Small high-need consumer segments remain key priority of Nuclear Medicine Radioisotopes distributors in the UK industry. Continuous launch of new products coupled with high expenditures support the market outlook. The UK Government financing remains the dominant funding source at 81.3% of total healthcare expenditure, or ?280 billion in 2025. According to the ONS, total healthcare spending grew 7.7% nominally and 3.9% in real terms from 2024 to 2025. Similarly, out-of-pocket spending was ?49 billion (14.1%) and voluntary health insurance was ?9.5 billion (2.8%). The market is driven by rapid digital adoption with NHS England’s plan to give more than 500,000 staff access to new AI tools.
China Nuclear Medicine Radioisotopes Market Growth Drivers, Revenue Trends, and Forecast- Medical insurance coverage is rapidly expanding over the past few years
China Nuclear Medicine Radioisotopes market is undergoing a structural shift from hospital-centric care toward a more integrated system emphasizing primary care, outpatient services, and long-term care. Chinese local players are emerging as a strong pillar of Nuclear Medicine Radioisotopes industry, offering opportunities for both competition and partnership. Over the forecast period, new and innovative product launches remain key elements driving market outlook. China's healthcare industry is increasingly centered on expanding healthcare capacity, improving access to advanced treatments, and reducing dependence on imported technologies.
The National Healthcare Security Administration reported that by end-2024, China’s basic medical insurance covered 1.32662 billion people and the coverage rate was 95%. Regional disparities in consumer spending trends continue to become more pronounced in the Chinese Nuclear Medicine Radioisotopes industry. Over the forecast period, demand will keep shifting toward geriatrics, chronic disease management, rehabilitation, long-term care, and outpatient care, while pricing pressure will remain intense in drugs and consumables because reimbursement.
India Nuclear Medicine Radioisotopes Market Landscape: Current Size and Long-Term Growth Outlook - Increased pricing pressures in US market is encouraging domestic vendors to expand across India
Indian Nuclear Medicine Radioisotopes market is witnessing the rapid emergence of an ecosystem that brings together diverse companies across the industry value chain. Further, large-scale healthcare public and private investments and a steady growth in chronic conditions is driving sales of pharmaceuticals and medical devices. Further, non-retail channel is experiencing volume decrease and patients are migrating to the retail. Indian medical device firms are also combining precision engineering with lower labor costs to make world-class diagnostics, robotics, and critical care devices.
Brazil Nuclear Medicine Radioisotopes market remains price-driven, with products domestically manufactured and accessibility offering potential opportunities
Healthcare expenditure in Brazil exceeds 10% of GDP, with the country among the highest healthcare spenders in Latin America. ANS reported 53.2 million medical-plan beneficiaries in December 2025, while IBGE projects a steady rise in older-age cohorts, with people aged 60+ already representing about 23% of the population. The price sensitive market access is broad through the public system, private coverage adds a sizeable premium layer, and reimbursement, procurement, and hospital efficiency remain key buying drivers.
Middle East and Africa Nuclear Medicine Radioisotopes Industry Trends and Perspectives to 2034
According to the World Bank, the Middle East and North Africa population exceeds 500 million, while Sub-Saharan Africa's population exceeds 1.2 billion, making the broader MEA region one of the fastest-growing healthcare demand centers globally. The GCC countries including Saudi Arabia, United Arab Emirates, Qatar, and Kuwait continue to account for a disproportionately large share of regional healthcare spending. Government-led programs such as Saudi Arabia's Vision 2030 are accelerating investments in hospital infrastructure, private-sector participation, medical technology adoption, and healthcare digitalization. On the other hand, South Africa, Egypt, Nigeria, and Kenya remain key healthcare markets due to their large populations, expanding private healthcare sectors, and growing investments in healthcare delivery systems.
Nuclear Medicine Radioisotopes Market Segmentation
By Type of Radioisotope
Diagnostic Radioisotopes
SPECT Radioisotopes
PET Radioisotopes
Therapeutic Radioisotopes
Alpha Emitters
Beta Emitters
Brachytherapy Isotopes
By Application
Oncology
Cardiology
Neurology
Thyroid and Endocrine Disorders
Other Applications
By Radiopharmaceutical Form
Injectable
Oral Capsules / Solutions
By End-User
Hospitals
Diagnostic and Imaging Centers
Academic and Research Institutes
Leading Companies in Nuclear Medicine Radioisotopes Industry (2026)
Curium
Cardinal Health, Inc.
Eckert & Ziegler Radiopharma
GE HealthCare Technologies Inc.
Telix Pharmaceuticals Ltd.
Lantheus Holdings, Inc.
BWX Technologies, Inc. (Nordion)
Jubilant Pharmova Limited
NTP Radioisotopes SOC Ltd.
Isotope Technologies Garching GmbH (ITM)
Countries Included
- North America- US, Canada, Mexico
- Europe- Germany, France, UK, Spain, Italy, Nordics, Others
- Asia Pacific- China, India, Japan, South Korea, Australia, Southeast Asia, Others
- Latin America- Brazil, Argentina, Others
- Middle East and Africa- Saudi Arabia, UAE, Other Middle East, South Africa, Other Africa
- Get Free print authentication across single, multi, and global licenses
- Free Accompanying excel spreadsheet with complete quantitative data
- Free 2-day consulting support from the lead analyst of the team that developed the report
- Gain clear understanding of current market conditions across 20 countries and plan your decisions accordingly
- Understand competitive profiles of the leading 15 companies in the Electrosurgical Generators industry
- Stay ahead of competition through a detailed analysis of recent market developments
- Make trusted decisions building on our 10-year experience in developing reports on Electrosurgical Generators industry
CHAPTER 1- EXECUTIVE SUMMARY
1.1. Market Snapshot: Market Size, CAGR, and Growth Outlook to 2034
1.2. Key Industry Highlights, 2026
1.3. Premium Market Insights
1.3.1. Potential Nuclear Medicine Radioisotopes Market Types and Applications
1.3.2. Fastest Growing Countries Over the forecast period
1.4. Market Scope and Segmentation
1.4.1. Key Market Segments
1.4.2. Key Countries and Regions
1.4.3. Top Companies in the Nuclear Medicine Radioisotopes Industry
1.5. Macroeconomic and Demographic Outlook
1.5.1. GDP Outlook by Top 20 Countries, 2010- 2040
1.5.2. Population Forecast by Country, 2010- 2040
1.5.3. Inflation Trends in Leading Countries
1.6. Impact of Trade Policies, Regulations, and Sustainability
1.6.1. Trade tariffs and localization requirements
1.6.2. ESG and sustainability pressures
1.6.3. Compliance-driven structural changes in the value chain
CHAPTER 2- RESEARCH METHODOLOGY
2.1. Report Coverage
2.2. Secondary Research
2.3. Primary Research
2.4. Data Triangulation
2.5. Market Modeling and Forecasting
CHAPTER 3- GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET TRENDS, GROWTH DRIVERS, CHALLENGES, AND OPPORTUNITIES THROUGH 2034
3.1. An Introduction to Global Nuclear Medicine Radioisotopes Markets in 2026
3.2. Global Historic and Forecast Nuclear Medicine Radioisotopes Market Size Outlook, USD Million, 2021- 2034
3.3. Annual Market Size Growth Rate (Y-o-Y), %, 2021-2034
3.4. Market Dynamics
3.4.1. Key Nuclear Medicine Radioisotopes Market Driving Forces and Their Impact on Market Outlook
3.4.2. Short and Long-Term Trends and Insights Shaping the Future
3.4.3. Potential Nuclear Medicine Radioisotopes Market Opportunities for Industry Stakeholders
3.4.4. Potential Challenges across Nuclear Medicine Radioisotopes Value Chain
CHAPTER 4- NUCLEAR MEDICINE RADIOISOTOPES MARKET COMPETITIVE LANDSCAPE, STRATEGIC ANALYSIS, AND VALUE CHAIN ASSESSMENT
4.1. Porter’s Five Forces Analysis
4.1.1. Bargaining Power of Buyers
4.1.2. Bargaining Power of Suppliers
4.1.3. Threat of Substitutes
4.1.4. Threat of New Entrants
4.1.5. Intensity of Competitive Rivalry
4.1.6. Market Attractiveness Analysis by Segment
4.1.7. Market Attractiveness Analysis by Region
4.2. Competitive Landscape
4.2.1 Market Share Analysis of Leading Nuclear Medicine Radioisotopes Companies
4.2.2 Recent Strategic Developments
4.2.3 Mergers, Acquisitions, and Partnerships
4.2.4 Product Launches and Innovation Trends
4.2.5 Key Success Factors
4.3. Value Chain Analysis
4.3.1. Key Value Chain Segments
4.3.2. Dominant players by value-chain stage
4.4. SWOT Analysis
4.4.1. Key Strengths and Opportunities
4.4.2. Major Weaknesses and Threats
4.5 Technology Roadmap
4.6 Regulatory and Reimbursement Landscape
CHAPTER 5- NUCLEAR MEDICINE RADIOISOTOPES MARKET OUTLOOK BY SEGMENTS
5.1. Market Size Outlook by Type, USD Million, 2021- 2025 and 2026-2034
5.2. Market Size Outlook by Application, USD Million, 2021- 2025 and 2026-2034
5.3. Market Size Outlook by Country, USD Million, 2021- 2025 and 2026-2034
By Type of Radioisotope
Diagnostic Radioisotopes
SPECT Radioisotopes
PET Radioisotopes
Therapeutic Radioisotopes
Alpha Emitters
Beta Emitters
Brachytherapy Isotopes
By Application
Oncology
Cardiology
Neurology
Thyroid and Endocrine Disorders
Other Applications
By Radiopharmaceutical Form
Injectable
Oral Capsules / Solutions
By End-User
Hospitals
Diagnostic and Imaging Centers
Academic and Research Institutes
CHAPTER 6- SCENARIO ANALYSIS AND OUTLOOK
6.1. Base Case Scenario
6.1.1. Definitions and Insights
6.1.2. Market Size Outlook to 2034
6.2. Low Growth Case Scenario
6.2.1. Definitions and Insights
6.2.2. Market Size Outlook to 2034
6.3. High Growth Case Scenario
6.3.1. Definitions and Insights
6.3.2. Market Size Outlook to 2034
CHAPTER 7- NORTH AMERICA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE ANALYSIS AND OUTLOOK
7.1. North America Nuclear Medicine Radioisotopes Market Overview, 2026
7.2. Leading Companies Operating in North America
7.3. Key Industry Statistics, 2026
7.4. North America Nuclear Medicine Radioisotopes Market Trends and Growth Opportunities to 2034
7.5. North America Nuclear Medicine Radioisotopes Market Size Outlook by Type
7.6. North America Nuclear Medicine Radioisotopes Market Size Outlook by Application
7.7. North America Nuclear Medicine Radioisotopes Market Size Outlook by Country
7.8. United States
7.8.1. Key Statistics
7.8.2. The US Nuclear Medicine Radioisotopes Market Size Outlook, 2021- 2034
7.8.3. Key Market Drivers and Industry Developments in the US Nuclear Medicine Radioisotopes Companies
7.9. Canada
7.9.1. Key Statistics
7.9.2. Canada Nuclear Medicine Radioisotopes Market Size Outlook, 2021- 2034
7.9.3. Key Market Drivers and Industry Developments in Canada Nuclear Medicine Radioisotopes Companies
7.10. Mexico
7.10.1. Key Statistics
7.10.2. Mexico Nuclear Medicine Radioisotopes Market Size Outlook, 2021- 2034
7.10.3. Key Market Drivers and Industry Developments in Mexico Nuclear Medicine Radioisotopes Companies
CHAPTER 8- EUROPE NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE ANALYSIS AND OUTLOOK
8.1. Europe Nuclear Medicine Radioisotopes Market Overview, 2026
8.2. Leading Companies Operating in Europe
8.3. Key Industry Statistics, 2026
8.4. Europe Nuclear Medicine Radioisotopes Market Trends and Growth Opportunities to 2034
8.5. Europe Nuclear Medicine Radioisotopes Market Size Outlook by Type
8.6. Europe Nuclear Medicine Radioisotopes Market Size Outlook by Application
8.7. Europe Nuclear Medicine Radioisotopes Market Size Outlook by Country
8.8. Germany
8.8.1. Key Statistics
8.8.2. Germany Nuclear Medicine Radioisotopes Market Size Outlook, 2021- 2034
8.8.3. Key Market Drivers and Industry Developments in Germany Nuclear Medicine Radioisotopes Companies
8.9. France
8.9.1. Key Statistics
8.9.2. France Nuclear Medicine Radioisotopes Market Size Outlook, 2021- 2034
8.9.3. Key Market Drivers and Industry Developments in France Nuclear Medicine Radioisotopes Companies
8.10. United Kingdom
8.10.1. Key Statistics
8.10.2. United Kingdom Nuclear Medicine Radioisotopes Market Size Outlook, 2021- 2034
8.10.3. Key Market Drivers and Industry Developments in the UK Nuclear Medicine Radioisotopes Companies
8.11. Spain
8.11.1. Key Statistics
8.11.2. Spain Nuclear Medicine Radioisotopes Market Size Outlook, 2021- 2034
8.11.3. Key Market Drivers and Industry Developments in Spain Nuclear Medicine Radioisotopes Companies
8.12. Italy
8.12.1. Key Statistics
8.12.2. Italy Nuclear Medicine Radioisotopes Market Size Outlook, 2021- 2034
8.12.3. Key Market Drivers and Industry Developments in Italy Nuclear Medicine Radioisotopes Companies
8.13. Rest of Europe
8.13.1. Key Statistics
8.13.2. Rest of Europe Nuclear Medicine Radioisotopes Market Size Outlook, 2021- 2034
8.13.3. Key Market Drivers and Industry Developments in Rest of Europe Nuclear Medicine Radioisotopes Companies
CHAPTER 9- ASIA PACIFIC NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE ANALYSIS AND OUTLOOK
9.1. Asia Pacific Nuclear Medicine Radioisotopes Market Overview, 2026
9.2. Leading Companies Operating in Asia Pacific
9.3. Key Industry Statistics, 2026
9.4. Asia Pacific Nuclear Medicine Radioisotopes Market Trends and Growth Opportunities to 2034
9.5. Asia Pacific Nuclear Medicine Radioisotopes Market Size Outlook by Type
9.6. Asia Pacific Nuclear Medicine Radioisotopes Market Size Outlook by Application
9.7. Asia Pacific Nuclear Medicine Radioisotopes Market Size Outlook by Country
9.8. China
9.8.1. Key Statistics
9.8.2. China Nuclear Medicine Radioisotopes Market Size Outlook, 2021- 2034
9.8.3. Key Market Drivers and Industry Developments in China Nuclear Medicine Radioisotopes Companies
9.9. Japan
9.9.1. Key Statistics
9.9.2. Japan Nuclear Medicine Radioisotopes Market Size Outlook, 2021- 2034
9.9.3. Key Market Drivers and Industry Developments in Japan Nuclear Medicine Radioisotopes Companies
9.10. India
9.10.1. Key Statistics
9.10.2. India Nuclear Medicine Radioisotopes Market Size Outlook, 2021- 2034
9.10.3. Key Market Drivers and Industry Developments in India Nuclear Medicine Radioisotopes Companies
9.11. South Korea
9.11.1. Key Statistics
9.11.2. South Korea Nuclear Medicine Radioisotopes Market Size Outlook, 2021- 2034
9.11.3. Key Market Drivers and Industry Developments in South Korea Nuclear Medicine Radioisotopes Companies
9.12. Australia
9.12.1. Key Statistics
9.12.2. Australia Nuclear Medicine Radioisotopes Market Size Outlook, 2021- 2034
9.12.3. Key Market Drivers and Industry Developments in Australia Nuclear Medicine Radioisotopes Companies
9.13. Southeast Asia
9.13.1. Key Statistics
9.13.2. Southeast Asia Nuclear Medicine Radioisotopes Market Size Outlook, 2021- 2034
9.13.3. Key Market Drivers and Industry Developments in Southeast Asia Nuclear Medicine Radioisotopes Companies
CHAPTER 10- SOUTH AND CENTRAL AMERICA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE ANALYSIS AND OUTLOOK
10.1. South and Central America Nuclear Medicine Radioisotopes Market Overview, 2026
10.2. Leading Companies Operating in South and Central America
10.3. Key Industry Statistics, 2026
10.4. South and Central America Nuclear Medicine Radioisotopes Market Trends and Growth Opportunities to 2034
10.5. South and Central America Nuclear Medicine Radioisotopes Market Size Outlook by Type
10.6. South and Central America Nuclear Medicine Radioisotopes Market Size Outlook by Application
10.7. South and Central America Nuclear Medicine Radioisotopes Market Size Outlook by Country
10.8. Brazil
10.8.1. Key Statistics
10.8.2. Brazil Nuclear Medicine Radioisotopes Market Size Outlook, 2021- 2034
10.8.3. Key Market Drivers and Industry Developments in Brazil Nuclear Medicine Radioisotopes Companies
10.9. Argentina
10.9.1. Key Statistics
10.9.2. Argentina Nuclear Medicine Radioisotopes Market Size Outlook, 2021- 2034
10.9.3. Key Market Drivers and Industry Developments in Argentina Nuclear Medicine Radioisotopes Companies
10.10. Rest of Latin America
10.10.1. Key Statistics
10.10.2. Rest of Latin America Nuclear Medicine Radioisotopes Market Size Outlook, 2021- 2034
10.10.3. Key Market Drivers and Industry Developments in Rest of Latin America Nuclear Medicine Radioisotopes Companies
CHAPTER 11- MIDDLE EAST AND AFRICA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE ANALYSIS AND OUTLOOK
11.1. Middle East and Africa Nuclear Medicine Radioisotopes Market Overview, 2026
11.2. Leading Companies Operating in Middle East and Africa
11.3. Key Industry Statistics, 2026
11.4. Middle East and Africa Nuclear Medicine Radioisotopes Market Trends and Growth Opportunities to 2034
11.5. Middle East and Africa Nuclear Medicine Radioisotopes Market Size Outlook by Type
11.6. Middle East and Africa Nuclear Medicine Radioisotopes Market Size Outlook by Application
11.7. Middle East and Africa Nuclear Medicine Radioisotopes Market Size Outlook by Country
11.8. Saudi Arabia
11.8.1. Key Statistics
11.8.2. Saudi Arabia Nuclear Medicine Radioisotopes Market Size Outlook, 2021- 2034
11.8.3. Key Market Drivers and Industry Developments in Saudi Arabia Nuclear Medicine Radioisotopes Companies
11.9. United Arab Emirates
11.9.1. Key Statistics
11.9.2. The UAE Nuclear Medicine Radioisotopes Market Size Outlook, 2021- 2034
11.9.3. Key Market Drivers and Industry Developments in the UAE Nuclear Medicine Radioisotopes Companies
11.10. Africa
11.10.1. Key Statistics
11.10.2. Africa Nuclear Medicine Radioisotopes Market Size Outlook, 2021- 2034
11.10.3. Key Market Drivers and Industry Developments in Africa Nuclear Medicine Radioisotopes Companies
CHAPTER 12- COMPANY PROFILES
12.1. Top Companies in Nuclear Medicine Radioisotopes Industry
Curium
Cardinal Health, Inc.
Eckert & Ziegler Radiopharma
GE HealthCare Technologies Inc.
Telix Pharmaceuticals Ltd.
Lantheus Holdings, Inc.
BWX Technologies, Inc. (Nordion)
Jubilant Pharmova Limited
NTP Radioisotopes SOC Ltd.
Isotope Technologies Garching GmbH (ITM)
12.2. Business Description
12.3. SWOT Profiles
12.4. Products and Services
CHAPTER 13- APPENDIX
Glossary of Terms
Research Methodology & Data Sources
Conclusion & Strategic Recommendations
1.1. Market Snapshot: Market Size, CAGR, and Growth Outlook to 2034
1.2. Key Industry Highlights, 2026
1.3. Premium Market Insights
1.3.1. Potential Nuclear Medicine Radioisotopes Market Types and Applications
1.3.2. Fastest Growing Countries Over the forecast period
1.4. Market Scope and Segmentation
1.4.1. Key Market Segments
1.4.2. Key Countries and Regions
1.4.3. Top Companies in the Nuclear Medicine Radioisotopes Industry
1.5. Macroeconomic and Demographic Outlook
1.5.1. GDP Outlook by Top 20 Countries, 2010- 2040
1.5.2. Population Forecast by Country, 2010- 2040
1.5.3. Inflation Trends in Leading Countries
1.6. Impact of Trade Policies, Regulations, and Sustainability
1.6.1. Trade tariffs and localization requirements
1.6.2. ESG and sustainability pressures
1.6.3. Compliance-driven structural changes in the value chain
CHAPTER 2- RESEARCH METHODOLOGY
2.1. Report Coverage
2.2. Secondary Research
2.3. Primary Research
2.4. Data Triangulation
2.5. Market Modeling and Forecasting
CHAPTER 3- GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET TRENDS, GROWTH DRIVERS, CHALLENGES, AND OPPORTUNITIES THROUGH 2034
3.1. An Introduction to Global Nuclear Medicine Radioisotopes Markets in 2026
3.2. Global Historic and Forecast Nuclear Medicine Radioisotopes Market Size Outlook, USD Million, 2021- 2034
3.3. Annual Market Size Growth Rate (Y-o-Y), %, 2021-2034
3.4. Market Dynamics
3.4.1. Key Nuclear Medicine Radioisotopes Market Driving Forces and Their Impact on Market Outlook
3.4.2. Short and Long-Term Trends and Insights Shaping the Future
3.4.3. Potential Nuclear Medicine Radioisotopes Market Opportunities for Industry Stakeholders
3.4.4. Potential Challenges across Nuclear Medicine Radioisotopes Value Chain
CHAPTER 4- NUCLEAR MEDICINE RADIOISOTOPES MARKET COMPETITIVE LANDSCAPE, STRATEGIC ANALYSIS, AND VALUE CHAIN ASSESSMENT
4.1. Porter’s Five Forces Analysis
4.1.1. Bargaining Power of Buyers
4.1.2. Bargaining Power of Suppliers
4.1.3. Threat of Substitutes
4.1.4. Threat of New Entrants
4.1.5. Intensity of Competitive Rivalry
4.1.6. Market Attractiveness Analysis by Segment
4.1.7. Market Attractiveness Analysis by Region
4.2. Competitive Landscape
4.2.1 Market Share Analysis of Leading Nuclear Medicine Radioisotopes Companies
4.2.2 Recent Strategic Developments
4.2.3 Mergers, Acquisitions, and Partnerships
4.2.4 Product Launches and Innovation Trends
4.2.5 Key Success Factors
4.3. Value Chain Analysis
4.3.1. Key Value Chain Segments
4.3.2. Dominant players by value-chain stage
4.4. SWOT Analysis
4.4.1. Key Strengths and Opportunities
4.4.2. Major Weaknesses and Threats
4.5 Technology Roadmap
4.6 Regulatory and Reimbursement Landscape
CHAPTER 5- NUCLEAR MEDICINE RADIOISOTOPES MARKET OUTLOOK BY SEGMENTS
5.1. Market Size Outlook by Type, USD Million, 2021- 2025 and 2026-2034
5.2. Market Size Outlook by Application, USD Million, 2021- 2025 and 2026-2034
5.3. Market Size Outlook by Country, USD Million, 2021- 2025 and 2026-2034
By Type of Radioisotope
Diagnostic Radioisotopes
SPECT Radioisotopes
PET Radioisotopes
Therapeutic Radioisotopes
Alpha Emitters
Beta Emitters
Brachytherapy Isotopes
By Application
Oncology
Cardiology
Neurology
Thyroid and Endocrine Disorders
Other Applications
By Radiopharmaceutical Form
Injectable
Oral Capsules / Solutions
By End-User
Hospitals
Diagnostic and Imaging Centers
Academic and Research Institutes
CHAPTER 6- SCENARIO ANALYSIS AND OUTLOOK
6.1. Base Case Scenario
6.1.1. Definitions and Insights
6.1.2. Market Size Outlook to 2034
6.2. Low Growth Case Scenario
6.2.1. Definitions and Insights
6.2.2. Market Size Outlook to 2034
6.3. High Growth Case Scenario
6.3.1. Definitions and Insights
6.3.2. Market Size Outlook to 2034
CHAPTER 7- NORTH AMERICA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE ANALYSIS AND OUTLOOK
7.1. North America Nuclear Medicine Radioisotopes Market Overview, 2026
7.2. Leading Companies Operating in North America
7.3. Key Industry Statistics, 2026
7.4. North America Nuclear Medicine Radioisotopes Market Trends and Growth Opportunities to 2034
7.5. North America Nuclear Medicine Radioisotopes Market Size Outlook by Type
7.6. North America Nuclear Medicine Radioisotopes Market Size Outlook by Application
7.7. North America Nuclear Medicine Radioisotopes Market Size Outlook by Country
7.8. United States
7.8.1. Key Statistics
7.8.2. The US Nuclear Medicine Radioisotopes Market Size Outlook, 2021- 2034
7.8.3. Key Market Drivers and Industry Developments in the US Nuclear Medicine Radioisotopes Companies
7.9. Canada
7.9.1. Key Statistics
7.9.2. Canada Nuclear Medicine Radioisotopes Market Size Outlook, 2021- 2034
7.9.3. Key Market Drivers and Industry Developments in Canada Nuclear Medicine Radioisotopes Companies
7.10. Mexico
7.10.1. Key Statistics
7.10.2. Mexico Nuclear Medicine Radioisotopes Market Size Outlook, 2021- 2034
7.10.3. Key Market Drivers and Industry Developments in Mexico Nuclear Medicine Radioisotopes Companies
CHAPTER 8- EUROPE NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE ANALYSIS AND OUTLOOK
8.1. Europe Nuclear Medicine Radioisotopes Market Overview, 2026
8.2. Leading Companies Operating in Europe
8.3. Key Industry Statistics, 2026
8.4. Europe Nuclear Medicine Radioisotopes Market Trends and Growth Opportunities to 2034
8.5. Europe Nuclear Medicine Radioisotopes Market Size Outlook by Type
8.6. Europe Nuclear Medicine Radioisotopes Market Size Outlook by Application
8.7. Europe Nuclear Medicine Radioisotopes Market Size Outlook by Country
8.8. Germany
8.8.1. Key Statistics
8.8.2. Germany Nuclear Medicine Radioisotopes Market Size Outlook, 2021- 2034
8.8.3. Key Market Drivers and Industry Developments in Germany Nuclear Medicine Radioisotopes Companies
8.9. France
8.9.1. Key Statistics
8.9.2. France Nuclear Medicine Radioisotopes Market Size Outlook, 2021- 2034
8.9.3. Key Market Drivers and Industry Developments in France Nuclear Medicine Radioisotopes Companies
8.10. United Kingdom
8.10.1. Key Statistics
8.10.2. United Kingdom Nuclear Medicine Radioisotopes Market Size Outlook, 2021- 2034
8.10.3. Key Market Drivers and Industry Developments in the UK Nuclear Medicine Radioisotopes Companies
8.11. Spain
8.11.1. Key Statistics
8.11.2. Spain Nuclear Medicine Radioisotopes Market Size Outlook, 2021- 2034
8.11.3. Key Market Drivers and Industry Developments in Spain Nuclear Medicine Radioisotopes Companies
8.12. Italy
8.12.1. Key Statistics
8.12.2. Italy Nuclear Medicine Radioisotopes Market Size Outlook, 2021- 2034
8.12.3. Key Market Drivers and Industry Developments in Italy Nuclear Medicine Radioisotopes Companies
8.13. Rest of Europe
8.13.1. Key Statistics
8.13.2. Rest of Europe Nuclear Medicine Radioisotopes Market Size Outlook, 2021- 2034
8.13.3. Key Market Drivers and Industry Developments in Rest of Europe Nuclear Medicine Radioisotopes Companies
CHAPTER 9- ASIA PACIFIC NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE ANALYSIS AND OUTLOOK
9.1. Asia Pacific Nuclear Medicine Radioisotopes Market Overview, 2026
9.2. Leading Companies Operating in Asia Pacific
9.3. Key Industry Statistics, 2026
9.4. Asia Pacific Nuclear Medicine Radioisotopes Market Trends and Growth Opportunities to 2034
9.5. Asia Pacific Nuclear Medicine Radioisotopes Market Size Outlook by Type
9.6. Asia Pacific Nuclear Medicine Radioisotopes Market Size Outlook by Application
9.7. Asia Pacific Nuclear Medicine Radioisotopes Market Size Outlook by Country
9.8. China
9.8.1. Key Statistics
9.8.2. China Nuclear Medicine Radioisotopes Market Size Outlook, 2021- 2034
9.8.3. Key Market Drivers and Industry Developments in China Nuclear Medicine Radioisotopes Companies
9.9. Japan
9.9.1. Key Statistics
9.9.2. Japan Nuclear Medicine Radioisotopes Market Size Outlook, 2021- 2034
9.9.3. Key Market Drivers and Industry Developments in Japan Nuclear Medicine Radioisotopes Companies
9.10. India
9.10.1. Key Statistics
9.10.2. India Nuclear Medicine Radioisotopes Market Size Outlook, 2021- 2034
9.10.3. Key Market Drivers and Industry Developments in India Nuclear Medicine Radioisotopes Companies
9.11. South Korea
9.11.1. Key Statistics
9.11.2. South Korea Nuclear Medicine Radioisotopes Market Size Outlook, 2021- 2034
9.11.3. Key Market Drivers and Industry Developments in South Korea Nuclear Medicine Radioisotopes Companies
9.12. Australia
9.12.1. Key Statistics
9.12.2. Australia Nuclear Medicine Radioisotopes Market Size Outlook, 2021- 2034
9.12.3. Key Market Drivers and Industry Developments in Australia Nuclear Medicine Radioisotopes Companies
9.13. Southeast Asia
9.13.1. Key Statistics
9.13.2. Southeast Asia Nuclear Medicine Radioisotopes Market Size Outlook, 2021- 2034
9.13.3. Key Market Drivers and Industry Developments in Southeast Asia Nuclear Medicine Radioisotopes Companies
CHAPTER 10- SOUTH AND CENTRAL AMERICA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE ANALYSIS AND OUTLOOK
10.1. South and Central America Nuclear Medicine Radioisotopes Market Overview, 2026
10.2. Leading Companies Operating in South and Central America
10.3. Key Industry Statistics, 2026
10.4. South and Central America Nuclear Medicine Radioisotopes Market Trends and Growth Opportunities to 2034
10.5. South and Central America Nuclear Medicine Radioisotopes Market Size Outlook by Type
10.6. South and Central America Nuclear Medicine Radioisotopes Market Size Outlook by Application
10.7. South and Central America Nuclear Medicine Radioisotopes Market Size Outlook by Country
10.8. Brazil
10.8.1. Key Statistics
10.8.2. Brazil Nuclear Medicine Radioisotopes Market Size Outlook, 2021- 2034
10.8.3. Key Market Drivers and Industry Developments in Brazil Nuclear Medicine Radioisotopes Companies
10.9. Argentina
10.9.1. Key Statistics
10.9.2. Argentina Nuclear Medicine Radioisotopes Market Size Outlook, 2021- 2034
10.9.3. Key Market Drivers and Industry Developments in Argentina Nuclear Medicine Radioisotopes Companies
10.10. Rest of Latin America
10.10.1. Key Statistics
10.10.2. Rest of Latin America Nuclear Medicine Radioisotopes Market Size Outlook, 2021- 2034
10.10.3. Key Market Drivers and Industry Developments in Rest of Latin America Nuclear Medicine Radioisotopes Companies
CHAPTER 11- MIDDLE EAST AND AFRICA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE ANALYSIS AND OUTLOOK
11.1. Middle East and Africa Nuclear Medicine Radioisotopes Market Overview, 2026
11.2. Leading Companies Operating in Middle East and Africa
11.3. Key Industry Statistics, 2026
11.4. Middle East and Africa Nuclear Medicine Radioisotopes Market Trends and Growth Opportunities to 2034
11.5. Middle East and Africa Nuclear Medicine Radioisotopes Market Size Outlook by Type
11.6. Middle East and Africa Nuclear Medicine Radioisotopes Market Size Outlook by Application
11.7. Middle East and Africa Nuclear Medicine Radioisotopes Market Size Outlook by Country
11.8. Saudi Arabia
11.8.1. Key Statistics
11.8.2. Saudi Arabia Nuclear Medicine Radioisotopes Market Size Outlook, 2021- 2034
11.8.3. Key Market Drivers and Industry Developments in Saudi Arabia Nuclear Medicine Radioisotopes Companies
11.9. United Arab Emirates
11.9.1. Key Statistics
11.9.2. The UAE Nuclear Medicine Radioisotopes Market Size Outlook, 2021- 2034
11.9.3. Key Market Drivers and Industry Developments in the UAE Nuclear Medicine Radioisotopes Companies
11.10. Africa
11.10.1. Key Statistics
11.10.2. Africa Nuclear Medicine Radioisotopes Market Size Outlook, 2021- 2034
11.10.3. Key Market Drivers and Industry Developments in Africa Nuclear Medicine Radioisotopes Companies
CHAPTER 12- COMPANY PROFILES
12.1. Top Companies in Nuclear Medicine Radioisotopes Industry
Curium
Cardinal Health, Inc.
Eckert & Ziegler Radiopharma
GE HealthCare Technologies Inc.
Telix Pharmaceuticals Ltd.
Lantheus Holdings, Inc.
BWX Technologies, Inc. (Nordion)
Jubilant Pharmova Limited
NTP Radioisotopes SOC Ltd.
Isotope Technologies Garching GmbH (ITM)
12.2. Business Description
12.3. SWOT Profiles
12.4. Products and Services
CHAPTER 13- APPENDIX
Glossary of Terms
Research Methodology & Data Sources
Conclusion & Strategic Recommendations
